Susceptibility to Pathogenic T Cells in Chronic Lung Disease May Have Genetic Basis

Discovery of Lung Stem Cell Subset Points to New Treatment Options

By Melinda Krigel

Respiratory viral infections pose significant morbidity and mortality to patients with chronic lung diseases like emphysema and COPD, causing exacerbations that drive destruction of normal lung tissue, and leading to one of the most common diagnoses for hospital admissions.

UC San Francisco researchers have uncovered a surprising role for fibroblasts in the lungs in activating T cell inflammation that drives lung destruction in COPD exacerbation triggered by viral infection. They also identified a T cell subset that can be targeted to treat COPD exacerbations.

In a study publishing February 22, 2023 in Immunity, first author Chaoqun Wang, PhD, a UCSF postdoctoral fellow in the laboratory of Tien Peng, MD, identified a fibroblast-secreted factor encoded by a COPD-susceptibility gene, HHIP, that suppresses viral inflammation in the lung. In collaboration with Ari Molofsky, MD, PhD, UCSF associate professor of Laboratory Medicine, the authors demonstrated that loss of HHIP promotes the expansion of tissue resident T cells that accumulate in the lung, leading to inflammatory destruction of resident lung stem cells.

The researchers discovered a pathogenic T cell subset (Tissue resident lymphocytes) in human emphysema using high-definition single cell sequencing of patient samples. They found that therapeutic targeting of these pathogenic T cells improves disease in pre-clinical models of emphysema.  

These findings shed important insights on why certain patients with COPD-susceptibility gene variants are more likely to develop worsening COPD and present a novel therapeutic approach to treat COPD progression through the restoration of tissue factors in the lung.  

“Discovery of a new lung stem cell subset in human emphysema lungs that is susceptible to these pathogenic T cells will provide more opportunity for therapeutic targeting of these pathogenic T cells to eventually improve disease treatment,” said Peng, UCSF associate professor of Medicine.

About UCSF Health: UCSF Health is recognized worldwide for its innovative patient care, reflecting the latest medical knowledge, advanced technologies and pioneering research. It includes the flagship UCSF Medical Center, which is ranked among the top 10 hospitals nationwide, as well as UCSF Benioff Children’s Hospitals, with campuses in San Francisco and Oakland, Langley Porter Psychiatric Hospital and Clinics, UCSF Benioff Children’s Physicians and the UCSF Faculty Practice. These hospitals serve as the academic medical center of the University of California, San Francisco, which is world-renowned for its graduate-level health sciences education and biomedical research. UCSF Health has affiliations with hospitals and health organizations throughout the Bay Area. Visit https://ucsfhealth.org. Follow UCSF Health on Facebook or on Twitter.